Chalid Assaf

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial

Rudolf Stadler, Rudolf Stadler, Pietro Quaglino, F J Sherida H Woei-A-Jin et autres

de, by, be, ch, gr, es, at, jp, gb, fr, us, it, hu, pl (code pays fourni par la source)

Tumor–Macrophage–Nerve interactions drive neuroinflammation and neuropathic pain in prostate cancer perineural invasion

Shaaban A. Mousa, Mohammed A. Shaqura, Doaa M. Mohamed, Xueqi Hong et autres

• Rat model of prostate cancer perineural invasion reproduces progressive pain. • Perineural tumors drive M1 macrophage influx and IL-1β/TNF-α upregulation. • Tumor–nerve crosstalk increases RANTES, VEGF, TIMP-1 and neuronal injury markers. • cAMP–CREB–ERK1/2 activation along pain pathways parallels hypersensitivity. • Intrathecal …

de (code pays fourni par la source)

Brentuximab Vedotin in Advanced-Stage Mycosis Fungoides/Sézary Syndrome with Low CD30 Expression: Real-World Data from the German Cutaneous Lymphoma Network

Christoph Blazejak, Mathias Oymanns, René Stranzenbach, Uwe Hillen et autres

Background/Objectives: Advanced-stage mycosis fungoides (MF) and Sézary syndrome (SS) are aggressive forms of cutaneous T-cell lymphoma (CTCL) for which treatment options are limited and prognosis is poor. Brentuximab vedotin (BV), an anti-CD30 antibody–drug conjugate, has demonstrated high response rates in patients with …

de (code pays fourni par la source)

Radioimmunotherapy combined with antibody–drug conjugate-induced radiosensitization leads to long-term remission of mycosis fungoides

Mathias Oymanns, Khaled A. Elsayad, Michael Daum-Marzian, Raed Abu-Dawud et autres

We evaluated a combination of brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam therapy in 14 patients with tumour-stage mycosis fungoides (MF). The overall response rate was 100%, with 64% of patients achieving complete remission; treatment was well tolerated, with limited …

de (code pays fourni par la source)

European Organisation for Research and Treatment of Cancer, United States Cutaneous Lymphoma Consortium and International Society for Cutaneous Lymphomas consensus recommendations for management and treatment of cutaneous lymphoproliferative disorders

Rein Willemze, Chalid Assaf, Martine. Bagot, Marie Beylot-Barry et autres

In recent classifications several cutaneous lymphomas were reclassified as lymphoproliferative disorder (LPDs). These include primary cutaneous CD4+ small/medium T-cell LPD (PCSM-TCLPD), primary cutaneous acral CD8+ T-cell LPD (acral CD8+ TCLPD) and primary cutaneous marginal zone lymphoma/LPD (PCMZL/LPD). The latter is still classified …

A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom

Chalid Assaf, Tim Illidge, Nathalie A. Waser, Mary He et autres

(1) Background: Most patients with mycosis fungoides (MF), a form of cutaneous T-cell lym-phoma (CTCL), develop relapsed/refractory (R/R) disease following front-line systemic therapy. This report describes treatment patterns and outcomes from the subpopulation with R/R MF. (2) Methods: This observational, retrospective, cohort …

us, gb, de, ch, es, it, fr (code pays fourni par la source)